PALISADE BIO, INC. Earnings Per Share (Basic)
PALISADE BIO, INC. (PALI) reported Earnings Per Share (Basic) of -$0.05 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- PALISADE BIO, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.05.
- PALISADE BIO, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.05.
- PALISADE BIO, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.38.
- PALISADE BIO, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$0.58.
- PALISADE BIO, INC. earnings per share, basic for fiscal 2025 was -$0.30.
- PALISADE BIO, INC. earnings per share, basic for fiscal 2024 was -$10.19.
- PALISADE BIO, INC. earnings per share, basic for fiscal 2023 was -$27.01.
- PALISADE BIO, INC. earnings per share, basic for fiscal 2022 was -$16.53.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.05 10-Q · filed 2026-08-10 | -$0.10 10-Q · filed 2026-08-10 | ||||||
| 2026-03-31 | -$0.05 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | -$0.30 10-K · filed 2026-03-20 | |||||||
| 2025-09-30 | -$0.38 10-Q · filed 2025-11-10 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.38 10-Q · filed 2025-11-10 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-08-10 | ||||
| 2025-06-30 | -$0.58 10-Q · filed 2026-08-10 | -$1.05 10-Q · filed 2026-08-10 | -$2.13 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-08-10 | ||||
| 2025-03-31 | -$0.47 10-Q · filed 2026-05-12 | -$1.60 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$5.43 derived: net income ÷ weighted average shares · filed 2026-05-12 | ||||
| 2024-12-31 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$3.73 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$6.69 derived: net income ÷ weighted average shares · filed 2026-03-20 | -$10.19 10-K · filed 2026-03-20 | ||||
| 2024-09-30 | -$2.32 10-Q · filed 2025-11-10 | -$5.55 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$9.50 10-Q · filed 2025-11-10 | -$13.67 derived: net income ÷ weighted average shares · filed 2025-11-10 | ||||
| 2024-06-30 | -$3.32 10-Q · filed 2025-08-11 | -$7.60 10-Q · filed 2025-08-11 | -$12.14 derived: net income ÷ weighted average shares · filed 2025-08-11 | -$18.29 derived: net income ÷ weighted average shares · filed 2025-08-11 | ||||
| 2024-03-31 | -$4.59 10-Q · filed 2025-05-12 | -$9.38 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$16.17 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$23.45 derived: net income ÷ weighted average shares · filed 2025-05-12 | ||||
| 2023-12-31 | -$4.81 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$11.89 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$19.49 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$27.01 10-K · filed 2025-03-24 | -$1.80 10-K · filed 2024-03-26 | |||
| 2023-09-30 | -$7.38 10-Q · filed 2024-11-12 | -$0.49 10-Q · filed 2023-11-09 | -$15.27 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$23.24 10-Q · filed 2024-11-12 | -$1.55 10-Q · filed 2023-11-09 | -$17.75 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||
| 2023-06-30 | -$7.93 10-Q · filed 2024-08-12 | -$0.53 10-Q · filed 2023-08-10 | -$16.03 10-Q · filed 2024-08-12 | -$1.07 10-Q · filed 2023-08-10 | -$11.60 derived: net income ÷ weighted average shares · filed 2024-08-12 | -$15.73 derived: net income ÷ weighted average shares · filed 2024-08-12 | ||
| 2023-03-31 | -$8.13 10-Q · filed 2024-05-13 | -$0.54 10-Q · filed 2023-05-11 | -$6.07 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$10.12 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$14.62 derived: net income ÷ weighted average shares · filed 2024-05-13 | |||
| 2022-12-31 | -$2.22 derived: net income ÷ weighted average shares · filed 2024-03-26 | -$5.76 derived: net income ÷ weighted average shares · filed 2024-03-26 | -$9.75 derived: net income ÷ weighted average shares · filed 2024-03-26 | -$16.53 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | -$4.10 10-Q · filed 2023-11-09 | -$0.08 10-Q · filed 2022-11-14 | -$9.18 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$18.40 10-Q · filed 2023-11-09 | -$0.37 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$5.77 10-Q · filed 2023-08-10 | -$0.12 10-Q · filed 2022-08-15 | -$17.91 10-Q · filed 2023-08-10 | -$0.36 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | -$12.96 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | -$0.05 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.14 derived: net income ÷ weighted average shares · filed 2023-03-22 | $37.77 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$142.95 10-K · filed 2023-03-22 | -$2.86 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $0.42 10-Q · filed 2022-11-14 | -$2.54 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$3.50 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$3.59 10-Q · filed 2022-08-15 | -$6.17 10-Q · filed 2022-08-15 | ||||||
| 2020-12-31 | -$1.53 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$2.19 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$3.72 10-K · filed 2022-03-17 | |||||
| 2020-09-30 | -$0.66 10-Q · filed 2021-11-12 | -$2.19 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | -$0.67 10-Q · filed 2021-08-23 | -$1.53 10-Q · filed 2021-08-23 | ||||||
| 2018-09-30 | -$0.12 10-Q · filed 2018-11-14 | -$0.30 10-Q · filed 2018-11-14 | ||||||
| 2017-09-30 | -$0.01 10-Q · filed 2018-11-14 | -$1.00 10-Q · filed 2018-11-14 | ||||||
| 2016-09-30 | -$0.59 10-Q · filed 2017-11-08 | -$1.96 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |